Hydroxyurea therapy for children with sickle cell disease: Describing how caregivers make this decision

BMC Research Notes

Volumn 8, Issue 1, 2015, Pages

  Creary, Susan ^a   Zickmund, Susan ^b   Ross, Diana ^c   Krishnamurti, Lakshmanan ^c   Bogen, Debra L ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Decision making; Hydroxyurea; Qualitative research; Sickle cell

Indexed keywords

ANTISICKLING AGENT; HYDROXYUREA;

ADOLESCENT; ANEMIA, SICKLE CELL; CAREGIVER; CHILD; DAILY LIFE ACTIVITY; DECISION MAKING; FEMALE; HUMAN; MALE; NURSING; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CAREGIVERS; CHILD; CHILD, PRESCHOOL; DECISION MAKING; FEMALE; HUMANS; HYDROXYUREA; MALE;

EID: 84939790474     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-015-1344-0     Document Type: Article

References (19)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Eng J Med. 1994;330:1639-44.
2. National Heart, Lung, and Blood Institute, Disease and Conditions Index: sickle cell anemia: who is at risk? http://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk.html. Published September 28, 2012. Accessed Nov 7 2012.
3. Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer. 2007;48:705-10.
4. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663-72.
5. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106:2269-75.
6. Yawn BP, Buchanan BR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-Based report by expert panel members. JAMA. 2014;312:1033-48.
7. Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005;79:107-13.
8. Lanzkron S, Haywood C, Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the sickle cell disease adult provider network. J Natl Med Assoc. 2008;100:968-73.
9. Haywood C, Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011;86:85-7.
10. Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, et al. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatr Blood Cancer. 2013;60:653-8.
11. Brandow AM, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol. 2010;85:611-3.
12. Miller W, Crabtree B. Doing qualitative research. Thousand Oaks: Sage; 1992.
13. Logan DE, Radcliffe J, Smith-Whitley K. Parent factors and adolescent sickle cell disease: associations with patterns of health service use. J Pediatr Psychol. 2002;27:475-84.
14. DeWalt DA, Hink A. Health literacy and child health outcomes: a systematic review of the literature. Pediatrics. 2009;124(Suppl 3):S265-74.
15. Armstrong FD, Lemanek KL, Pegelow CH, et al. Impact of lifestyle disruption on parent and child coping, knowledge, and parental discipline in children with sickle cell anemia. Child Health Care. 1993;22:189-203.
16. Slap GB, Plotkin SL, Khalid N, et al. A human immunodeficiency virus peer education program for adolescent females. J Adolesc Health. 1991;12:434-42.
17. Miller MK, Zimmerman SA, Schultz WH, Ware RE. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol. 2001;2:306-8.
18. Meyappan JD, Lampl M, Hsu LL. Parents' assessment of risk in sickle cell disease treatment with hydroxyurea. J Pediatr Hematol Oncol. 2005;27:644-50.
19. Crosby LE, Shook LM, Ware RE, Brinkman WB. (2014) Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia. Pediatr Blood Cancer (Epub ahead of print).